Nano Nuclear reported no revenue for Q1 FY2026 and a net loss of 4300000, primarily driven by operating and research and development expenses. The company ended the quarter with 577500000 in cash after completing a 400000000 oversubscribed private placement, positioning it with substantial liquidity to advance its KRONOS MMR program.
Revenue was 0 for the quarter as the company remains in development stage.
Net loss totaled 4300000 for Q1 FY2026.
Cash and cash equivalents increased to 577500000 following financing activities.
400000000 private placement significantly strengthened the balance sheet.
The company did not provide quantitative financial guidance but highlighted anticipated milestones in 2026 including licensing submissions, potential partnerships, and further vertical integration progress.
Analyze how earnings announcements historically affect stock price performance